Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder (Q34579202)

3 August 2017

title

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder (English)

1 reference

3 August 2017

2

Siegfried Kasper

0 references

author name string

Jean Pierre Olié

series ordinal

1

1 reference

3 August 2017

publication date

4 May 2007

1 reference

The International Journal of Neuropsychopharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

10

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

661-673

1 reference

Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Selective serotonin-reuptake inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Effects of 5-HT(2) receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Antidepressants in clinical practice: limitations of assessment methods and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Activation of 5-HT2C receptors acutely induces Per gene expression in the rat suprachiasmatic nucleus at night

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Severe depression: is there a best approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

SSRI Antidepressant Medications: Adverse Effects and Tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Changes in forebrain function from waking to REM sleep in depression: preliminary analyses of [18F]FDG PET studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Changes in sleep architecture following chronic mild stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Melatonin enhances sexual behavior in the male rat

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Modulation of voltage-dependent Ca2+ conductance by changing Cl- concentration in rat lactotrophs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Circadian rhythm mechanisms in affective illness and in antidepressant drug action

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

A comparison of melatonin secretion in depressed patients and normal subjects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707007766

7 January 2021

10.1017/S1461145707007766

Identifiers

DOI

0 references

1 reference